Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. (Q37960391)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Leon I Igel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Amanda G Powell

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Louis J Aronne

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

Current Atherosclerosis Reports

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

60-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22113707%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11883-011-0221-0

17 January 2020

exact match

0 references

cites work

Prevalence and trends in obesity among US adults, 1999-2008

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Annual medical spending attributable to obesity: payer-and service-specific estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Obesity and disease management: effects of weight loss on comorbid conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Gastrointestinal hormones and weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Pramlintide and the treatment of diabetes: a review of the data since its introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Pharmacologic therapies for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Drug treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

Weight management in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-011-0221-0

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

12 December 2020

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

12 December 2020

Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.

1 reference

12 December 2020

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

1 reference

12 December 2020

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

1 reference

12 December 2020